AEON Biopharma, Inc. — Form S-1/A
Filed July 9, 2026 · analyzed by the Registration Agent
S-1/A
— Neutral
significance 8/100
What the filing says
AEON Biopharma filed Amendment No. 1 to S-1 on July 9, 2026, as a pre-effective exhibits-only amendment to update the Calculation of Filing Fee Table (Exhibit 107). The amendment reflects the proposed maximum aggregate offering price of Class A common stock underlying Five-Year Milestone Warrants at 115% of the assumed public offering price and adjusts the associated registration fee accordingly. No material business, financial, or operational changes are disclosed.
Why this rating
Routine pre-effective amendment adjusting warrant offering mechanics and filing fees; administrative and procedural, immaterial to company trajectory or valuation despite micro-cap size.
See more from July 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.